Palazestrant

N/A

Report date: 2026/05/16 20:00:17
NME

Base Information

Drug NamePalazestrant
Drug Alias NameOP-1250
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEstrogen receptors antagonists
TargetsEstrogen receptors
Therapy Area/IndicationsMetastatic breast cancerBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[27
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesOlema Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A